Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy
- 1 April 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical and Experimental Nephrology
- Vol. 12 (2), 119-125
- https://doi.org/10.1007/s10157-007-0011-8
Abstract
Background Serotonin (5-HT) is involved in vascular inflammation and atherosclerogenesis. Serum 5-HT concentrations are elevated in diabetes, and 5-HT is involved in diabetic vasculopathies. Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, has renoprotective effects, but its effect in diabetic nephropathy is not elucidated. The aim of this study was to examine the effects of sarpogrelate on endothelial dysfunction in rats with streptozotocin (STZ)-induced diabetes. Methods Rats with STZ-induced diabetes were either untreated or treated with sarpogrelate (30 mg/kg P.O.) for 8 weeks. At the end of the experiment, we measured urinary albumin excretion, serum adiponectin concentration and platelet-derived microparticles. Intraglomerular coagulation was detected by immunostaining for platelets. Production of renal reactive oxygen species (ROS) and nitric oxide (NO) was investigated by confocal laser microscopy and used as an index of glomerular endothelial dysfunction. Results Diabetic nephropathy was associated with enhanced production of ROS and diminished bioavailable NO in the glomeruli. Treatment with sarpogrelate improved ROS/NO imbalance in glomeruli, suppressed platelet aggregation in glomeruli, reduced platelet-derived microparticles, increased serum adiponectin level and reduced the level of albuminuria, compared with non-treated diabetic rats. Conclusions Our results indicate that sarpogrelate improves endothelial function in rats with STZ-induced diabetes through a reduction of glomerular platelet activation and an increase in serum adiponectin concentrations and suggest that sarpogrelate is potentially useful for the treatment of diabetic nephropathy.Keywords
This publication has 31 references indexed in Scilit:
- Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic NephropathyJournal of the American Society of Nephrology, 2007
- Serum Adiponectin and Renal Dysfunction in Men With Type 2 DiabetesDiabetes Care, 2007
- NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathyAmerican Journal of Physiology-Renal Physiology, 2005
- Conjunctive Effects of the 5HT2 Receptor Antagonist, Sarpogrelate, on Thrombolysis with Modified Tissue Plasminogen Activator in Different Laser-Induced Thrombosis ModelsPathophysiology of Haemostasis and Thrombosis, 2000
- THE 5‐HT2 RECEPTOR ANTAGONIST SARPOGRELATE REDUCES URINARY AND PLASMA LEVELS OF THROMBOXANE A2 AND URINARY ALBUMIN EXCRETION IN NON‐INSULIN‐DEPENDENT DIABETES MELLITUS PATIENTS†Clinical and Experimental Pharmacology and Physiology, 1999
- Serotonin enhances the production of type IV collagen by human mesangial cellsKidney International, 1998
- Anti-mitogenic effects of sarpogrelate in cultured rat mesangial cellsLife Sciences, 1997
- Cardiovascular Effects of Serotonin Agonists and AntagonistsJournal of Cardiovascular Pharmacology, 1990
- Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular diseaseEuropean Journal of Clinical Investigation, 1988
- Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetesBMJ, 1988